Clinical Trial Update: Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating eslicarbazepine acetate as add-on therapy for adults with refractory partial epilepsy; results assess efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Epilepsy

Drugs mentioned

• eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Partial Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2013-08-05